Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6WN2D)

Drug Name
ABT-308 Drug Info
Indication
Disease Entry ICD 11 Status REF
Eosinophilic esophagitis DA24.1 Phase 2 [1]
Asthma CA23 Phase 1 [2]
Cross-matching ID
TTD Drug ID
DM6WN2D

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Interleukin 13 receptor alpha-2 (IL13RA2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tralokinumab DM6ENSJ Atopic dermatitis EA80 Approved [3]
ICT-107 DMBIZ7H Brain cancer 2A00 Phase 3 [4]
MB-101 DMLA1QD Recurrent glioblastoma 2A00.00 Phase 1 [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 13 receptor alpha-2 (IL13RA2) TTMPZ7V I13R2_HUMAN Antagonist [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT00986037) Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Asthma. U.S. National Institutes of Health.
3 Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.Am J Respir Cell Mol Biol.2014 May;50(5):985-94.
4 Clinical pipeline report, company report or official report of ImmunoCellular Therapeutics.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)